Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
Trial details
- Registry ID
- NCT07010159
- Drugs studied
- KPL-387
TrialRedline tracks 4 clinical trials sponsored by Kiniksa Pharmaceuticals International, plc: 2 Phase 2 / 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387NCT07010159 | KPL-387 | Recruiting | 2027-12-31Estimated |
| Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationNCT04447469 | mavrilimumab | Completed | 2021-11-12Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Transition to KPL-387 Monotherapy Dosing & Administration StudyNCT07288216 | KPL-387 | Recruiting | 2027-12-31Estimated |
| A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's DiseaseNCT06531395 | Abiprubart | Terminated | 2025-03-06Actual |
Names as written in the registry records.
NCT07288216 · Kiniksa Pharmaceuticals International, plc
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Posology: Proportion of participants free from Pericarditis Recurrence by Week 16 Time frame: From first administration of study drug up to Week 16 Measure: Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE. Time frame: Up to 24 Months. After: Measure: Posology: Proportion of participants free from Pericarditis Recurrence by Week 16 Time frame: From baseline up to Week 16 Measure: Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE. Time frame: Up to 24 Months.
Before: 80 participants (planned). After: 120 participants (planned).
NCT07010159 · Kiniksa Pharmaceuticals International, plc
Before: 165 participants (planned). After: 325 participants (planned).
NCT07288216 · Kiniksa Pharmaceuticals International, plc
Before: Not yet recruiting. After: Recruiting.